Market Overview

UPDATE: Rodman & Renshaw Maintains Outperform on Cytokinetics; $2 PT


Rodman & Renshaw reiterated an Outperform rating on Cytokinetics (NASDAQ: CYTK) and a target price of $2.

Rodman & Renshaw wrote, “We expect management to provide further details on omecamtiv mecarbil's planned Phase II trials with oral formulations. Management announced last week that the company has selected oral formulations of omecamtiv mecarbil in order to advance the compound into Phase II clinical trials. The selection of oral compounds was based on data reviewed from the recently completed Phase I clinical trial, which was a randomized, open-label study designed to establish the bioavailability of oral formulations of omecamtiv mecarbil in healthy volunteers.”

Cytokinetics closed at $0.73 on Monday.

Posted-In: Rodman & RenshawAnalyst Color Reiteration Analyst Ratings


Related Articles (CYTK)

View Comments and Join the Discussion!

Latest Ratings

VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Rodman & Redshaw Reiterates Outperform on Alynlam Pharmaceuticals; $22 PT

ForexLive Asia Wrap Up